Success Metrics

Clinical Success Rate
100.0%

Based on 11 completed trials

Completion Rate
100%(11/11)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
7%
Ph phase_2
7
50%
Ph phase_1
6
43%

Phase Distribution

6

Early Stage

7

Mid Stage

1

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
6(42.9%)
Phase 2Efficacy & side effects
7(50.0%)
Phase 3Large-scale testing
1(7.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

84.6%

11 of 13 finished

Non-Completion Rate

15.4%

2 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(11)
Terminated(2)
Other(1)

Detailed Status

Completed11
Withdrawn2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (42.9%)
Phase 27 (50.0%)
Phase 31 (7.1%)

Trials by Status

completed1179%
unknown17%
withdrawn214%

Recent Activity

0 active trials
Showing 5 of 14
completedphase_2

A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer

NCT01656538
unknownphase_1

Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma

NCT03015922
completedphase_1

Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

NCT01274624
completedphase_1

Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

NCT02620423
withdrawnphase_1

REO13 Melanoma With of Without GM-CSF

NCT03282188
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT01656538Phase 2

A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer

Completed
NCT03015922Phase 1

Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma

Unknown
NCT01274624Phase 1

Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

Completed
NCT02620423Phase 1

Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Completed
NCT03282188Phase 1

REO13 Melanoma With of Without GM-CSF

Withdrawn
NCT02723838Phase 1

Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder

Withdrawn
NCT00998192Phase 2

A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung

Completed
NCT00861627Phase 2

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation

Completed
NCT00998322Phase 2

A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma

Completed
NCT00984464Phase 2

Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Completed
NCT01166542Phase 3

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

Completed
NCT00753038Phase 2

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma

Completed
NCT00503295Phase 2

Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung

Completed
NCT00528684Phase 1

Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas

Completed

All 14 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
14